ResearcherBeatson West of Scotland Cancer CentreActive in the last 2 years
Derek B. Grose
Matched on ORCID iD 0000-0002-2532-1818; OpenAlex author ID A5085896023. Sources: OpenAlex.
Their work
- Papers
- 8
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 59
2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 8
- Corrigendum to "SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer" [Radiother. Oncol. 155 … Co-author DOI 10.1016/j.radonc.2026.111610↗
- SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. Co-author DOI 10.1016/j.radonc.2020.11.007↗
- Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". Co-author DOI 10.1038/s41416-020-01133-8↗
- Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. Co-author DOI 10.1038/s41416-020-0980-x↗
- Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
- The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Co-author DOI 10.21037/jgo.2017.04.01↗
- Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.08.001↗
- A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. Co-author DOI 10.1186/s12885-016-2765-4↗
Closest collaborators
The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- D. Holyoake · 6 shared papers, 2016–2026 · strength 0.74
- Paper Corrigendum to "SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pa… DOI 10.1016/j.radonc.2026.111610↗
- Paper SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. DOI 10.1016/j.radonc.2020.11.007↗
- Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
- Ganesh Radhakrishna · 6 shared papers, 2016–2026 · strength 0.74
- Paper Corrigendum to "SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pa… DOI 10.1016/j.radonc.2026.111610↗
- Paper SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. DOI 10.1016/j.radonc.2020.11.007↗
- Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
- M. Hawkins · 6 shared papers, 2016–2026 · strength 0.74
- Paper Corrigendum to "SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pa… DOI 10.1016/j.radonc.2026.111610↗
- Paper SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. DOI 10.1016/j.radonc.2020.11.007↗
- Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
- Somnath Mukherjee · 5 shared papers, 2016–2021 · strength 0.43
- Paper SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. DOI 10.1016/j.radonc.2020.11.007↗
- Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
- Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
- Nigel Balfour Jamieson · 4 shared papers, 2017–2021 · strength 0.31
- Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
- Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
- Paper The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. DOI 10.21037/jgo.2017.04.01↗
- James S. Good · 2 shared papers, 2020–2021 · strength 0.19
- Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
- Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
- Paula Ghaneh · 2 shared papers, 2020–2021 · strength 0.19
- Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
- Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
- Katharine L. Aitken · 2 shared papers, 2020–2021 · strength 0.19
- Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
- Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
- Christopher Mark Jones · 2 shared papers, 2020–2021 · strength 0.19
- Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
- Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
- Daniel H. Palmer · 2 shared papers, 2020–2021 · strength 0.19
- Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
- Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
- Juan W. Valle · 2 shared papers, 2020–2021 · strength 0.19
- Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
- Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
- Pippa G. Corrie · 2 shared papers, 2020–2021 · strength 0.19
- Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
- Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
- Colin J. McKay · 2 shared papers, 2017–2019 · strength 0.12
- Paper The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. DOI 10.21037/jgo.2017.04.01↗
- Paper Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level … DOI 10.1093/jnci/djz073↗
- Janet Shirley Graham · 1 shared paper, 2017 · strength 0.06
- Andrew H. Ko · 1 shared paper, 2019 · strength 0.06
- Matthew H. G. Katz · 1 shared paper, 2019 · strength 0.06
- Christoph Tinchon · 1 shared paper, 2019 · strength 0.06
- Stephen John Clarke · 1 shared paper, 2019 · strength 0.06
- Jaswinder Singh Samra · 1 shared paper, 2019 · strength 0.06
- Kyu‐pyo Kim · 1 shared paper, 2019 · strength 0.06
- Martin D. McCarter · 1 shared paper, 2019 · strength 0.06
- Eric A. Mellon · 1 shared paper, 2019 · strength 0.06
- Johanna W. Wilmink · 1 shared paper, 2019 · strength 0.06
- Niek A. Peters · 1 shared paper, 2019 · strength 0.06
- Jessica M. Frakes · 1 shared paper, 2019 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.